DAS-001
Phase 2- Indications
- Myasthenia gravis
Company intelligence / Profile preview
DAS-MG, Inc.
Boston, Massachusetts, United Statesncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
DAS-MG is conducting a Phase II clinical trial for DAS-001, a fixed-dose combination tablet that combines pyridostigmine (the gold standard first-line treatment for myasthenia gravis) with an antagonist (ondansetron) to mitigate the gastrointestinal side effects of pyridostigmine[3].
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesCombination therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on DAS-MG, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DAS-MG, Inc..